 CAMBRIDGE, Mass.--BUSINESS WIRE--EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, today announced a late-breaking mini oral presentation of updated data from its partner CStone Pharmaceuticals Phase 3 GEMSTONE-302 study at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer IASLC 2021 WCLC. GEMSTONE-302 is a placebo-controlled Phase 3 trial evaluating 